Contents

Volume 82 Issue 6 | ARD June 2023

Editorial
727  Greetings from the editor 2023/2
J S Smolen

Reviews
M Kostopoulos, A Fanioukidis, G Bensias, D T Bousmpas

734  Site of invasion revisited: epigenetic drivers of joint destruction in RA
C Ospehl

Views on news
740  At the crossroads of inflammation and fibrosis: epiregulin
S O’Reilly

Recommendations
742  2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infectious diseases in adults with autoimmune inflammatory rheumatic diseases

754  2015 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

763  Instrument selection for the ASAS core outcome set for axial spondyloarthritis

778  Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force

Rheumatoid arthritis
799  Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage
T Li, C Ca, A Krammer, O Sorens, M Lea Aghili, L Johannson, K Fordina, E Lindef, M Yang, B Xu, Q Li, L Cheng, C Bogerström, C Fernandez, A Kastrem, S Ramqvist-Dahlblad, I Gjerstson, R Holmdahl

Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance

Psoriatic arthritis
820  Uptake and effectiveness of new biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries

More Contents ►
Myositis

829
Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

Vasculitis

837
Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

848
Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis
S R Henderson, H Horsfield, P Frankel, M Khosravi, T Goble, S Carter, M Antonelou, R D R Evans, X Zhang, T-Y Chu, H-H Lin, S Gordon, A D Sallama

Treatment

857
Efficacy and safety of emapalumab in macrophage activation syndrome
F De Benedetti, A A Grom, P A Bregan, C Bracaglia, M Parello, C Marucci, D Eleftheriou, C Papadopoulou, C Sciallet, P Quartier, J Antin, C Lavelle, R Frederiksen, V Ausnagi, M Ballabio, P Jazmin, C de Min

Osteoarthritis

866
Increased risk of osteoarthritis in patients with atopic disease
M C Baker, K Sheh, R Lu, D Lu, E P von Kaeppeler, A Blatt, D T Felton, W H Robinson

873
Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect

Letters

881
BlyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
S Gai, Z Hu, Y Chen, Y Chen, B Ming, R Gao, Z Li, C Ye, J Zhong, L Dong

883
Persistence of seroconversion in 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Eular news

886
News from EULAR
EULAR Communications

Electronic pages

e128
Correspondence on ‘Statistical review: frequently given comments’ by Waki et al
S Lydersen

e129
Response to: ‘Correspondence on ‘Statistical review: frequently given comments’ by Waki et al’
S Lydersen

e130

e131
Response to: ‘Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’ by C et al
K M D Silva, N Serling-Boyd, T Y-T Hsu, J A Sparks, Z S Wallace

e132
Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’
D Tampe, P Korsen, S Hakobsh, M S Windler, B Tampe

e133
Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’ by Tampe et al
M A Friedman, K L Winthrop
| e134 | Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
| A Kaklamanos, P Karamichalos, P G Vlachoyiannopoulos, A G Tzioufas |
| e135 | Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al
| S Ramin, R I M Mostard, R B M Landewé |
| e136 | Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’
| R Roongta, A Chattopadhyay, A Ghosh |
| e137 | Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al
| Y F A M Derksen, D van der Woude |
| e138 | Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
| J T Rosenbaum, M H Weisman, C Shaffer, E Askanyan, R A Howard, K Ogle, H Hamilton, J D Reveille, K I. Windroy, D Choi |
| e139 | Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Rosenbaum et al
| e140 | Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
| R M Flood, R Conway, C Kirby, D Ghetal, D J Kane, R H Mullan |
| e141 | Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’
| T-K Lin, L-F Pan, G-F Jong |
| e142 | Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’
| Z Gong, F Zhang |
| e143 | Response to: ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’’ by Gong and Zhang and Lin et al
| S Abati, J H M Driessen, A M Burden, P C Soweren, J P van den Berg, A Boonen |
| e144 | Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus’
| E D Batu, U Kaya Akca, O Basaran, Y Bilgner, S Ozcan |
| e145 | Response to: ‘Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus’’ by Batu et al
| C Adamichev, G Berissi |
| e146 | Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’
| A Hocevar, A Ambroži, M Tomičet |
| e147 | Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al
| P Gauckler, E I. Bentac, A Krómbichler |
| e148 | Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial’
| L de Wolff, S Arends, G M Verspagen, A Vissink, F G M Koese, H Botsma |
| e149 | Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by de Wolff et al
| R Felten, J-E Gottenberg |
| e150 | Correspondence on ‘Warfarin use and risk of knee and hip replacements’
| C Cheng, F Zhang |
| e151 | Response to: ‘Correspondence on ‘Warfarin use and risk of knee and hip replacements’’ by Cheng and Zhang
| T Neogi, C Pelsuvin, P Ballal, C G Boer |
| e152 | Paradoxical gastrointestinal effects of interleukin-17 blockers
| P Mehdi, A Lawrence, A Aggarwal |